Cybersecurity for BCIs, neuromodulation, and implantable neural devices.
Brain-computer interfaces and neuromodulation systems represent the most safety-critical class of connected medical devices. A cyber compromise can directly affect cognition, motor control, or therapeutic stimulation. We help NeuroTech manufacturers meet FDA's 2026 premarket cybersecurity expectations with threat models, SBOMs, and penetration testing tuned to implantable and wearable neural systems.
NeuroTech and brain-computer interfaces sit at the intersection of implantable hardware, real-time signal processing, and cloud analytics. A single compromised parameter can change cognition, motor control, or therapeutic stimulation - so reviewers and IRBs treat the cybersecurity package as a patient-safety document, not an IT artifact.
Most programs we support combine an implant or wearable, a clinician programmer, a patient remote or app, and a cloud back-end for adherence and outcome data. Each interface has its own threat model, and FDA expects them documented as a system, not as isolated components.
Typical clinical uses
Key data flows & integrations
BLE and proprietary RF links to clinician programmers must be authenticated and replay-resistant - unauthenticated stimulation parameter changes can cause direct patient harm.
Implantable firmware updates require signed, attested update channels with rollback protection and out-of-band recovery paths.
Patient-facing apps frequently ship with hardcoded keys, weak TLS pinning, and over-permissioned cloud APIs.
Neuromodulation devices combine an implant, a patient remote, a clinician programmer, and increasingly a cloud back-end. Closed-loop sensing adds a latency-bound integrity requirement on top of the standard wireless surface.
Layers shown outermost (top) to innermost (bottom). Dashed rows are part of the surrounding system but out of scope for this view.
NeuroTech vulnerabilities rarely produce headline incidents because deployed implant fleets are still small - but the underlying components share a stack with cardiac implants, infusion pumps, and BLE peripherals where extensive public failure history exists.
Historical incidents
The 2019 URGENT/11 advisory disclosed 11 vulnerabilities in the VxWorks IPnet TCP/IP stack used in many implantable controllers, programmers, and bedside monitors. FDA issued a Safety Communication directing manufacturers across implant categories - including neuromodulation - to assess and disclose exposure.
FDA Safety Communication, Oct 2019CISA ICSMA-19-274-01
Public research on SweynTooth (2020) and BrakTooth (2021) showed that BLE/Classic stacks shipped in widely used SoCs could be crashed or coerced into unauthenticated states by malformed packets - directly applicable to patient remotes and clinician programmers paired with neuromodulators.
CISA ICSMA-20-063-02CVE-2019-16336 et al.
Multiple manufacturers have disclosed account-takeover or PHI-exposure incidents in patient-facing apps for implantable devices. Reviewers now treat the patient app as in-scope for premarket cyber even when it does not directly program the implant.
Active threat scenarios
Unauthenticated or weakly authenticated write paths from a clinician programmer or patient remote allow stimulation parameters to be replayed or coerced to a default-permissive state.
Firmware updates that lack signature verification, anti-rollback, and atomic install create a path to permanent compromise of a long-deployed implant.
In closed-loop neuromodulation, fabricated or replayed neural input can drive the controller into clinically inappropriate stimulation if input authenticity and bounds are not enforced.
Neural recordings are irrevocable biometrics; broken object-level authorization (BOLA) on cloud APIs is a high-impact and frequently overlooked finding.
What FDA reviewers cite
Implantable and wearable neural systems sit on the highest-stakes safety/security boundary in MedTech - a single compromised stimulation parameter can cause direct patient harm.
OTA updates to implants are slow, power-constrained, and risk-controlled - your premarket design must minimize the need for them and document the secure update path FDA expects.
Unlike a password, neural and biometric data can't be rotated. Cloud architecture, retention, and access controls must reflect that.
When sensors, controllers, and stimulators come from different vendors, threat-model boundaries and interface contracts have to be explicit in your submission.
Implant cryptography selected today must remain defensible for 10+ years - including post-quantum migration planning.
What FDA scrutinizes
FDA expects a full SPDF: threat model, SBOM, security risk assessment tied to ISO 14971, security testing summary, and labeling - all consistent with the rest of the submission.
Reviewers want explicit analysis of how spoofed or replayed neural input is detected and how the device fails safely.
10-15 year implant lifetimes require a documented CVD process, SBOM monitoring, and a tested update mechanism.
Standards & deliverables
Six deliverables FDA and notified bodies expect across MedTech, with the neurotech / bci-specific wrinkle on each row. Use it as a scoping checklist before you brief vendors or your QA team.
Machine-readable SBOM (CycloneDX/SPDX) plus VEX feed for every CVE that touches a listed component.
Continuous CVE / advisory monitoring against the SBOM, with a documented triage and disclosure path.
Black/grey-box testing across device, wireless interfaces, mobile apps, cloud APIs, and service tooling.
STRIDE-per-interface threat model with documented mitigations and residual-risk acceptance.
Signed firmware/software updates with rollback protection, integrity verification, and staged rollout.
Public CVD policy, intake channel, and SLAs for triage, fix, and customer communication.
No - cybersecurity documentation is part of your 510(k), De Novo, or PMA, not a separate submission. We deliver an eSTAR-ready package aligned to the FDA 2026 final premarket cybersecurity guidance, AAMI SW96, and the IEC 14971 risk file. The cyber artifacts cross-reference the rest of the submission so reviewers can trace each control from threat to test to label.
We use SDR-based protocol analysis to capture and characterize the link, fuzzing of BLE and proprietary RF stacks (including downgrade and pairing-mode abuse), and authenticated gray-box testing of the clinician programmer. Replay, MITM, and spoofing of stimulation parameter writes are exercised on staging hardware only, never on a clinical system. Findings tie back to specific hazard entries in the IEC 14971 risk file so safety and security teams act on the same evidence.
Yes. Programmer and patient remote are modeled as part of the same system boundary as the implant, and we test programmer-to-implant and remote-to-implant paths - including pairing, session management, key custody, and stimulation-parameter authorization. Findings on either accessory feed back into the implant threat model so the system view stays coherent and reviewable.
Closed-loop systems get a dedicated control-integrity analysis: sensing-to-stimulation latency, signal authenticity, fail-safe behavior under spoofed or replayed neural input, and integrity of any in-loop adaptation. Crypto and integrity checks must hold within the clinically acceptable timing window, so we measure end-to-end timing and budget primitives accordingly. The SPDF documents the budget, the chosen primitives, and the fail-safe behavior tied to specific hazards.
We document end-of-life cyber expectations in the SPDF and labeling: key destruction, telemetry shutoff, data retention boundaries on patient remotes, and any forensic-readiness obligations. Explanted device handling (chain of custody, data extraction controls, secure disposal) is addressed because explanted neural implants can carry sensitive biometric data that cannot be rotated like a password.
Yes. Long-lived neural implants are exactly the use case FDA cites for needing a documented CVD process, SBOM monitoring, and a postmarket update plan under section §524B. We deliver the CVD policy, public intake (e.g., security.txt, vendor portal), acknowledgment and remediation SLAs, and the QMS process from CVE to controlled software change as part of the premarket package.
Cryptography selected today must remain defensible across the implant's deployed lifetime, so the design includes explicit crypto agility: algorithm identifiers in protocol headers, key rotation procedures, primitive deprecation paths, and a documented post-quantum migration plan. The SPDF and the postmarket plan describe how a primitive becomes obsolete and how the deployed fleet is migrated without loss of therapy continuity.
Neural recordings are sensitive biometric data and irrevocable - they can't be rotated. Cloud architecture, retention, and access controls reflect that: minimization at the source, encryption at rest and in transit, key custody, region/residency, audit logging, and explicit retention windows. Multi-tenant authorization is exercised aggressively because a single BOLA in this segment exposes continuous neural data for many patients.
When sensors, controllers, and stimulators come from different vendors, threat-model boundaries and interface contracts are made explicit in the submission. Each interface is enumerated with its protocol, authentication, integrity, and failure mode, and each vendor is treated as an explicit untrusted-but-contractually-bound party. The SPDF cross-references the integration test plan so reviewers can verify that the cleared system survives realistic adversarial conditions across the boundary.
Typical baseline: FDA 2026 final premarket cybersecurity guidance, AAMI SW96, AAMI TIR57, IEC 62304 (Class C for active implantables), ISO 14971, IEC 60601-1 with applicable particulars, IEC 81001-5-1 for the secure software lifecycle, and ISO 14708 series for active implantables. EU manufacturers add MDR Annex I §17.2 and MDCG 2019-16; we map artifacts across both regimes so you don't redo work.
For a new connected neural implant with programmer, patient remote, and cloud telemetry, end-to-end premarket cyber work generally runs 12-18 weeks. Threat modeling and SBOM front-load in weeks 1-5, pen testing across implant link, programmer, remote, and cloud runs in weeks 5-14, and the consolidated submission package and postmarket plan close in the final weeks - all under a written deficiency commitment.
30-minute discovery call - fixed-fee proposal within 24-hours, no surprises.
"Blue Goat's niche expertise in FDA-facing cybersecurity made all the difference. Their reports were built with the FDA's expectations in mind; it gave us confidence that we were submitting exactly what reviewers want to see."
Cybersecurity for BCIs, neuromodulation, and implantable neural devices.
